Janux Therapeutics (JANX)

• Market cap: $838M
• 1 day: 1.33%
• 5 days: 1.18%
• 1 month: -1.08%
• 3 months: -1.01%
• 6 months: -9.13%
• Year to date: 0.66%
• 1 year: -41.8%
• 5 years: -26.05%
• 10 years: -45.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Employees: 108